ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 249 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,505,995 | -31.7% | 696,065 | -21.5% | 0.92% | -23.6% |
Q2 2023 | $21,230,559 | +27.2% | 886,453 | -0.1% | 1.20% | +27.1% |
Q1 2023 | $16,695,711 | +9.5% | 887,126 | -7.4% | 0.95% | +8.5% |
Q4 2022 | $15,246,393 | +77.9% | 957,688 | +82.8% | 0.87% | +75.9% |
Q3 2022 | $8,571,000 | +11.9% | 523,870 | -3.6% | 0.50% | +34.3% |
Q2 2022 | $7,658,000 | -31.8% | 543,528 | +17.3% | 0.37% | -17.2% |
Q1 2022 | $11,221,000 | +4.3% | 463,304 | +0.5% | 0.45% | +17.0% |
Q4 2021 | $10,761,000 | +30.4% | 461,051 | -7.2% | 0.38% | +25.2% |
Q3 2021 | $8,251,000 | -34.0% | 496,757 | -3.1% | 0.30% | -31.5% |
Q2 2021 | $12,509,000 | -15.5% | 512,882 | -10.6% | 0.44% | -7.9% |
Q1 2021 | $14,808,000 | +1.0% | 573,936 | +109.3% | 0.48% | -6.4% |
Q4 2020 | $14,657,000 | +29.2% | 274,159 | -0.3% | 0.52% | +12.9% |
Q3 2020 | $11,343,000 | +21.9% | 274,979 | +43.2% | 0.46% | +14.5% |
Q2 2020 | $9,304,000 | +12.3% | 191,958 | -2.1% | 0.40% | -13.8% |
Q1 2020 | $8,285,000 | – | 196,095 | – | 0.46% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |